Zaneta Nikolovska-Coleska

This inventor holds 17 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Small Molecule Inhibitors. Top assignees: University of Michigan, Wayne State University. Active years: 2010-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zaneta Nikolovska-Coleska. Retrieved from https://idiyas.com/inventor/zaneta-nikolovska-coleska

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 3)

% Patents Active = 52.9

CIPO Patents = 2

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 5.5

ph-index = 6

Forward Citations = 137(Granted Patents)

Company Filing History:

17 out of 3,550

University of Michigan

patents

1 out of 605

Wayne State University

patents

where one patent can have more than one assignee

Years Active: 2010-2018

Loading Chart...

Areas of Expertise:

Small Molecule Inhibitors

Mcl-1

MDM2

Smac Mimetics

BCL-2 Family

XIAP Family

Compositions

Diazo Bicyclic

Heteroaryl-Substituted

Bivalent

Conformationally Constrained

Antagonists

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9914723 - Small molecule inhibitors of Mcl-1 and uses thereof (2018-03-13),

2. 9884841 - Small molecule inhibitors of Mcl-1 and uses thereof (2018-02-06),

3. 9862746 - Compositions and methods relating to hindering DOT1L recruitment by MLL-fusion proteins (2018-01-09),

4. 9486422 - Small molecule inhibitors of Mcl-1 and the uses of thereof (2016-11-08),

5. 9394303 - Small molecule inhibitors of MCL-1 and uses thereof (2016-07-19),

6. 8901117 - Small molecule inhibitors of MDM2 and the uses thereof (2014-12-02),

7. 8664212 - Diazo bicyclic Smac mimetics and the uses thereof (2014-03-04),

8. 8557812 - Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof (2013-10-15),

9. 8445473 - Heteroaryl-substituted bicyclic Smac mimetics and the uses thereof (2013-05-21),

10. 8278293 - Diazo bicyclic Smac mimetics and the uses thereof (2012-10-02),

11. 8202902 - Bivalent SMAC mimetics and the uses thereof (2012-06-19),

12. 8088931 - Small molecule inhibitors of MDM2 and the uses thereof (2012-01-03),

13. 7960372 - Bivalent Smac mimetics and the uses thereof (2011-06-14),

14. 7932382 - Conformationally constrained Smac mimetics and the uses thereof (2011-04-26),

15. 7910621 - Small molecule antagonists of XIAP family proteins (2011-03-22),

Title: Zaneta Nikolovska-Coleska: Innovator in Medicinal Chemistry

Introduction

Zaneta Nikolovska-Coleska is a prominent inventor based in Ann Arbor, MI (US). She has made significant contributions to the field of medicinal chemistry, particularly in the development of small molecule inhibitors for therapeutic applications.

Latest Patents

Zaneta holds 17 patents, with her latest inventions focusing on small molecule inhibitors of Mcl-1. One of her notable patents describes a new class of small molecules featuring a [(1-Piperazinyl)-4-pyridinylmethyl]-Naphtho[1,2-b]furan structure. These molecules function as inhibitors of the Mcl-1 protein and are intended for use as therapeutics in treating cancer and other diseases. Another patent also addresses small molecule inhibitors of Mcl-1, specifically those with a benzoic acid structure, further emphasizing her innovative approach to cancer treatment.

Career Highlights

Zaneta has worked at esteemed institutions such as the University of Michigan and Wayne State University. Her research has significantly advanced the understanding and treatment of various diseases through innovative medicinal chemistry.

Collaborations

Zaneta has collaborated with notable colleagues, including Shaomeng Wang and Haiying Sun, contributing to her success in the field.

Conclusion

Zaneta Nikolovska-Coleska's work in medicinal chemistry exemplifies her dedication to innovation and the development of effective cancer therapies. Her contributions continue to impact the scientific community and improve patient outcomes.

Profile summary based on public USPTO records.